SALT LAKE CITY / Jun 05, 2023 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at the Jefferies Healthcare Conference.
Management will participate in a fireside chat presentation on Wednesday, June 7, 2023 at 3:30pm EST. The presentation will be webcast live and may be accessed through the following link: https://wsw.com/webcast/jeff281/vrex/1883310.
A replay of the presentation will be available on Varex’s website at www.vareximaging.com/news. The replay will be available for 90 days after the presentation.
About Varex
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,400 people located in North America, Europe, and Asia. For more information visit vareximaging.com.
| Last Trade: | US$7.32 |
| Daily Change: | 0.16 2.23 |
| Daily Volume: | 821,744 |
| Market Cap: | US$301.800M |
February 03, 2025 December 23, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
